Windward Bio Group AG, a private clinical-stage biotechnology company, has closed a USD 165 million Series B financing round. Windward Bio is committed to improving outcomes for people living with serious immunological diseases.
act legal Switzerland (formerly BGPartner Ltd) acted as Swiss counsel to OrbiMed (lead investor), Novo Holdings, Blue Owl Capital and Omega Funds, advising on all Swiss law aspects of the Series B financing and on the related negotiations. The team consisted of Oliver Gnehm, Victoria Marty, Tessa Douma and Céline Meier.












